RedHill Biopharma (RDHL) Competitors

$0.40

+0.02 (+5.31%)

(As of 07/26/2024 ET)

RDHL vs. MEIP, MGTA, BTAI, INAB, CUE, PMN, LIAN, NKGN, ICCC, and VYNE

Should you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include MEI Pharma (MEIP), Magenta Therapeutics (MGTA), BioXcel Therapeutics (BTAI), IN8bio (INAB), Cue Biopharma (CUE), ProMIS Neurosciences (PMN), LianBio (LIAN), NKGen Biotech (NKGN), ImmuCell (ICCC), and VYNE Therapeutics (VYNE). These companies are all part of the "medical" sector.

RedHill Biopharma vs.

RedHill Biopharma (NASDAQ:RDHL) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

: RedHill Biopharma has a beta of 3.64, indicating that its stock price is 264% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
: RedHill Biopharma received 42 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 67.99% of users gave RedHill Biopharma an outperform vote while only 61.11% of users gave MEI Pharma an outperform vote.
Company Underperform Outperform
RedHill Biopharma Outperform Votes
427
67.99%
Underperform Votes
201
32.01%
MEI Pharma Outperform Votes
385
61.11%
Underperform Votes
245
38.89%
: RedHill Biopharma has higher earnings, but lower revenue than MEI Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RedHill Biopharma $6.53M 1.80 $23.92M N/A N/A
MEI Pharma $48.82M 0.49 -$31.84M $3.92 0.92
: MEI Pharma has a consensus target price of $7.00, indicating a potential upside of 94.99%. Given MEI Pharma's higher probable upside, analysts clearly believe MEI Pharma is more favorable than RedHill Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RedHill Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
MEI Pharma
0 Sell rating(s)

3 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, MEI Pharma had 7 more articles in the media than RedHill Biopharma. MarketBeat recorded 12 mentions for MEI Pharma and 5 mentions for RedHill Biopharma. RedHill Biopharma's average media sentiment score of 0.37 beat MEI Pharma's score of -0.15 indicating that RedHill Biopharma is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RedHill Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MEI Pharma
0 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: MEI Pharma's return on equity of 48.32% beat RedHill Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
RedHill Biopharma N/A N/A N/A
MEI Pharma N/A 48.32% 28.13%
: 7.2% of RedHill Biopharma shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 6.8% of RedHill Biopharma shares are owned by insiders. Comparatively, 3.9% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Underperform	Outperform
RedHill Biopharma	Outperform Votes 427 67.99%	Underperform Votes 201 32.01%
MEI Pharma	Outperform Votes 385 61.11%	Underperform Votes 245 38.89%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RedHill Biopharma	$6.53M	1.80	$23.92M	N/A	N/A
MEI Pharma	$48.82M	0.49	-$31.84M	$3.92	0.92

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RedHill Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
MEI Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RedHill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MEI Pharma	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
RedHill Biopharma	N/A	N/A	N/A
MEI Pharma	N/A	48.32%	28.13%

Summary

RedHill Biopharma beats MEI Pharma on 7 of the 13 factors compared between the two stocks.

Ad Porter & Company

Nvidia insiders dumping shares

All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.

To see Porter Stansberry's new AI prediction go here now.

Get RedHill Biopharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export to Excel

Metric	RedHill Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.79M	$7.10B	$5.28B	$8.22B
Dividend Yield	N/A	2.81%	2.80%	3.96%
P/E Ratio	N/A	12.87	140.55	16.25
Price / Sales	1.80	289.14	2,039.46	80.24
Price / Cash	0.27	32.58	35.28	34.13
Price / Book	3.61	5.89	4.95	4.50
Net Income	$23.92M	$147.89M	$111.27M	$216.46M
7 Day Performance	9.22%	2.76%	2.53%	1.55%
1 Month Performance	6.64%	10.12%	11.18%	7.63%
1 Year Performance	-70.39%	1.93%	9.65%	2.80%

RedHill Biopharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEIP MEI Pharma	4.4288 of 5 stars 4.43 / 5 stars	$3.47 +21.3%	$7.00 +101.7%	-53.0%	$23.11M	$48.82M	0.89	100	Analyst Downgrade Short Interest ↓ High Trading Volume
MGTA Magenta Therapeutics	0 of 5 stars 0.00 / 5 stars	$0.70 -7.7%	N/A	+72.7%	$42.44M	N/A	0.00	67	News Coverage Gap Down
BTAI BioXcel Therapeutics	4.5481 of 5 stars 4.55 / 5 stars	$1.20 +2.6%	$11.80 +883.3%	-88.9%	$45.04M	$1.38M	-0.23	90	Short Interest ↓
INAB IN8bio	3.4773 of 5 stars 3.48 / 5 stars	$0.87 +4.8%	$10.00 +1,046.0%	-40.5%	$38.50M	N/A	-0.96	20	Short Interest ↓
CUE Cue Biopharma	4.1784 of 5 stars 4.18 / 5 stars	$0.77 +1.3%	$8.00 +938.8%	-82.3%	$37.46M	$5.49M	-0.73	60	Analyst Forecast Short Interest ↓ News Coverage
PMN ProMIS Neurosciences	2.3622 of 5 stars 2.36 / 5 stars	$1.93 -7.7%	$8.00 +314.5%	-48.9%	$36.60M	$10,000.00	-2.61	5	Short Interest ↑ News Coverage Gap Down
LIAN LianBio	0.8555 of 5 stars 0.86 / 5 stars	$0.31 -3.1%	$5.33 +1,615.4%	-85.4%	$33.60M	N/A	-0.38	110	Gap Down
NKGN NKGen Biotech	0 of 5 stars 0.00 / 5 stars	$1.28 +7.6%	N/A	N/A	$32.99M	$80,000.00	0.00	N/A
ICCC ImmuCell	0 of 5 stars 0.00 / 5 stars	$4.19 +0.7%	N/A	-24.7%	$32.72M	$17.47M	-8.22	70
VYNE VYNE Therapeutics	2.517 of 5 stars 2.52 / 5 stars	$2.10 -1.4%	$5.75 +173.8%	-43.4%	$30.51M	$420,000.00	-0.39	30